Safety and efficacy of 6% hydroxyethyl starch in patients undergoing major surgery: The randomised controlled PHOENICS trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Buhre Wolfgang, Díaz-Cambronero Óscar, Schaefer Simon, Novacek Martin, Domingo Marina Soro, Stessel Bjorn, Rodríguez-Pérez Aurelio, Richter Torsten, Rohe Georg, Cholley Bernard, Gruenewald Matthias, Kuiper Gerhardus, Jaber Samir, de Korte Dianne, Belda Javier, de Abreu Marcelo Gama, Baronica Robert, Scheeren Thomas, Ferrando-Ortolá Carlos, Szczeklik Wojciech, Tomescu Dana, Vyzamal Tomas, Gavranovic Zejka, Argente-Navarro María Pilar, Mazzinari Guido, Thaler Sarah, García-Gregorio Nuria, Vandenbrande Jeroen, Zlotnik Diane, Wittenstein Jakob, Schmier Sonja, Rohn Susanne, Glasmacher Christoph, Holler Martin, Jungheinrich Cornelius, Niess Ulf, Sessler Daniel I, Westphal Martin, New Collective Author
Аннотация
OBJECTIVE: We studied if the peri-operative use of HES is noninferior to crystalloids in terms of acute kidney injury. Secondary outcome was the noninferiority of HES on worsening of renal injury and/or the incidence of a composite endpoint of major complications and mortality until postoperative day 90.
DESIGN: Randomised double-blind trial in patients undergoing elective abdominal surgery with expected blood loss at least 500 ml.
SETTING: Multicentre trial at 53 study sites in 10 European countries.
PATIENTS: One thousand nine hundred and eighty-five (HES 977, crystalloid-only 981) patients aged 40 to 85 years with ASA status II-III.
INTERVENTION: Either 6% HES 130/0.4 or a crystalloid solution. Dosing was guided by mean arterial pressure and/or routine haemodynamic variables.
MAIN OUTCOME MEASURE: Change from pre-operative to lowest cystatin C-based eGFR during the first 3 postoperative days. Key secondary outcome was a composite endpoint of mortality and major postoperative complications after 90 days.
RESULTS: Mean change in eGFR from baseline to minimum was -3.4 ± 17.7 ml min -1 1.73 m -2 in HES patients and -1.0 ± 17.1 ml min -1 1.73 m -2 in crystalloid-only patients ( P < 0.001 for noninferiority). The key secondary endpoint occurred in 35% of patients in each group. There were no clinically relevant differences in any safety endpoint including 90-day renal function. Any cause mortality-difference until the end of 1-year follow-up was not significantly different (8.6% in HES and 10.1% in crystalloid patients).
CONCLUSION: Peri-operative use of HES was noninferior to crystalloids in short-term renal function or a composite of mortality and major complications at 90 days. PHOENICS provides robust evidence that peri-operative in-label use of HES is well tolerated.
TRIAL REGISTRATION AND FUNDING: EudraCT no. 2016-002162-30, clinicaltrials.gov ID NCT03278548.